Literature DB >> 14551507

Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis.

Hitoshi Niikura1, Toshimitsu Koizumi, Kiyoshi Ito, Kunihiro Okamura, Nobuo Yaegashi.   

Abstract

We report on three cases of long-term dialysis patients with gynecological malignancies who were successfully treated with chemotherapy. Two epithelial ovarian carcinoma patients were treated with a single agent, carboplatin (100-200 mg/m2). One recurrent endometrial carcinoma patient was treated with carboplatin (200 mg/m2) and paclitaxel (135 mg/m2). Hemodialysis was started 2 h after the carboplatin infusion and lasted 4 h in all three cases. All patients tolerated these therapies without significant myelosuppression or severe side-effects. Our findings suggest these regimens are feasible, and the combination of paclitaxel and carboplatin is effective chemotherapy when administered to long-term hemodialysis patients with recurrent endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551507     DOI: 10.1097/00001813-200310000-00008

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

1.  Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency.

Authors:  Nozomu Tanji; Tetsuya Fukumoto; Noriyoshi Miura; Yutaka Yanagihara; Akitomi Shirato; Koji Azuma; Yuki Miyauchi; Tadahiko Kikugawa; Kenji Shimamoto; Masayoshi Yokoyama
Journal:  Int J Clin Oncol       Date:  2012-08-31       Impact factor: 3.402

2.  Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.

Authors:  Joan B Heijns; Maria E L van der Burg; Teun van Gelder; Marien W J A Fieren; Peter de Bruijn; Ate van der Gaast; Walter J Loos
Journal:  Cancer Chemother Pharmacol       Date:  2008-01-19       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.